369 related articles for article (PubMed ID: 29894814)
1. Permeability of glibenclamide through a PAMPA membrane: The effect of co-amorphization.
Ruponen M; Visti M; Ojarinta R; Laitinen R
Eur J Pharm Biopharm; 2018 Aug; 129():247-256. PubMed ID: 29894814
[TBL] [Abstract][Full Text] [Related]
2. The effect of co-amorphization of glibenclamide on its dissolution properties and permeability through an MDCKII-MDR1 cell layer.
Sormunen H; Ruponen M; Laitinen R
Int J Pharm; 2019 Oct; 570():118653. PubMed ID: 31472218
[TBL] [Abstract][Full Text] [Related]
3. Dissolution and Permeability Properties of Co-Amorphous Formulations of Hydrochlorothiazide.
Ruponen M; Rusanen H; Laitinen R
J Pharm Sci; 2020 Jul; 109(7):2252-2261. PubMed ID: 32315662
[TBL] [Abstract][Full Text] [Related]
4. Amino acids as co-amorphous excipients for simvastatin and glibenclamide: physical properties and stability.
Laitinen R; Löbmann K; Grohganz H; Strachan C; Rades T
Mol Pharm; 2014 Jul; 11(7):2381-9. PubMed ID: 24852326
[TBL] [Abstract][Full Text] [Related]
5. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
[TBL] [Abstract][Full Text] [Related]
6. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
[TBL] [Abstract][Full Text] [Related]
7. Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs.
Ruponen M; Kettunen K; Santiago Pires M; Laitinen R
Pharmaceutics; 2021 Jan; 13(2):. PubMed ID: 33514009
[TBL] [Abstract][Full Text] [Related]
8. Co-former selection for co-amorphous drug-amino acid formulations.
Kasten G; Löbmann K; Grohganz H; Rades T
Int J Pharm; 2019 Feb; 557():366-373. PubMed ID: 30578980
[TBL] [Abstract][Full Text] [Related]
9. Dipeptides as co-formers in co-amorphous systems.
Wu W; Löbmann K; Schnitzkewitz J; Knuhtsen A; Pedersen DS; Rades T; Grohganz H
Eur J Pharm Biopharm; 2019 Jan; 134():68-76. PubMed ID: 30468836
[TBL] [Abstract][Full Text] [Related]
10. Investigation into the Solid-State Properties and Dissolution Profile of Spray-Dried Ternary Amorphous Solid Dispersions: A Rational Step toward the Design and Development of a Multicomponent Amorphous System.
Baghel S; Cathcart H; O'Reilly NJ
Mol Pharm; 2018 Sep; 15(9):3796-3812. PubMed ID: 30020788
[TBL] [Abstract][Full Text] [Related]
11. New metastable form of glibenclamide prepared by redispersion from ternary solid dispersions containing polyvinylpyrrolidone-K30 and sodium lauryl sulfate.
Thongnopkoon T; Puttipipatkhachorn S
Drug Dev Ind Pharm; 2016 Jan; 42(1):70-79. PubMed ID: 25835067
[TBL] [Abstract][Full Text] [Related]
12. The effect of drug and EUDRAGIT® S 100 miscibility in solid dispersions on the drug and polymer dissolution rate.
Higashi K; Hayashi H; Yamamoto K; Moribe K
Int J Pharm; 2015 Oct; 494(1):9-16. PubMed ID: 26253374
[TBL] [Abstract][Full Text] [Related]
13. Tannic acid as a co-former in co-amorphous systems: Enhancing their physical stability, solubility and dissolution behavior.
Fael H; Demirel AL
Int J Pharm; 2020 May; 581():119284. PubMed ID: 32243965
[TBL] [Abstract][Full Text] [Related]
14. Influence of Solid Drug Delivery System Formulation on Poorly Water-Soluble Drug Dissolution and Permeability.
Krstić M; Popović M; Dobričić V; Ibrić S
Molecules; 2015 Aug; 20(8):14684-98. PubMed ID: 26287134
[TBL] [Abstract][Full Text] [Related]
15. Biomimetic Dissolution: A Tool to Predict Amorphous Solid Dispersion Performance.
Puppolo MM; Hughey JR; Dillon T; Storey D; Jansen-Varnum S
AAPS PharmSciTech; 2017 Nov; 18(8):2841-2853. PubMed ID: 28560506
[TBL] [Abstract][Full Text] [Related]
16. Preparation and Evaluation of Co-amorphous Formulations of Telmisartan-Amino Acids as a Potential Method for Solubility and Dissolution Enhancement.
Khanfar M; Al-Remawi M; Al-Akayleh F; Hmouze S
AAPS PharmSciTech; 2021 Mar; 22(3):112. PubMed ID: 33748914
[TBL] [Abstract][Full Text] [Related]
17. Transformations between Co-Amorphous and Co-Crystal Systems and Their Influence on the Formation and Physical Stability of Co-Amorphous Systems.
Wu W; Wang Y; Löbmann K; Grohganz H; Rades T
Mol Pharm; 2019 Mar; 16(3):1294-1304. PubMed ID: 30624075
[TBL] [Abstract][Full Text] [Related]
18. Dissolution properties of co-amorphous drug-amino acid formulations in buffer and biorelevant media.
Heikkinen AT; DeClerck L; Löbmann K; Grohganz H; Rades T; Laitinen R
Pharmazie; 2015 Jul; 70(7):452-7. PubMed ID: 26373205
[TBL] [Abstract][Full Text] [Related]
19. Mechanism-based selection of stabilization strategy for amorphous formulations: Insights into crystallization pathways.
Edueng K; Mahlin D; Larsson P; Bergström CAS
J Control Release; 2017 Jun; 256():193-202. PubMed ID: 28412224
[TBL] [Abstract][Full Text] [Related]
20. Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin-arginine.
Lenz E; Jensen KT; Blaabjerg LI; Knop K; Grohganz H; Löbmann K; Rades T; Kleinebudde P
Eur J Pharm Biopharm; 2015 Oct; 96():44-52. PubMed ID: 26197392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
